OBJECTIVES: Thymic carcinomas have wide ranges of reported survival. Interobserver agreement on diagnosis might affect prognostical studies. Clinicopathological features of thymic carcinomas were compared with thymic epithelial neoplasms in which pathologists disagreed upon.
INTRODUCTION
Thymic carcinomas are very uncommon malignancies. They represent 2-28% of all thymic epithelial neoplasms [1] and have an incidence of only 1-5 cases per million population per year [2] . Thymic carcinomas are a heterogeneous group of tumours that frequently metastasize and recur with the reported 10-year survival ranging from 0 to 67% [1] . The extent of the disease at the time of presentation often precludes surgical intervention. For instance, in a study by Okereke et al. [3] , only 13% (16 of 125) of patients with thymic carcinoma eventually underwent resection.
Because of the low frequency of thymic carcinomas and the relatively low rate of resectability, there is a paucity of literature concerning the clinical features of this patient population, pathological findings of their tumours and follow-up.
Although defined by the World Health Organization (WHO), the reproducibility of thymic epithelial neoplasms can be problematic and might be a source for its controversial prognostical value. Interobserver agreements for the WHO classification of thymic epithelial neoplasms has been only moderate, with nonweighted k values of 0.45-0.475, and common disagreements occur for type B3 thymoma vs thymic carcinoma [4, 5] .
We retrospectively studied the clinicopathological features of thymic carcinomas in which all thoracic pathologists had independently agreed upon the diagnosis. We compared these results with a group of thymic epithelial neoplasms in which the thoracic pathologists had disagreed but with at least one pathologist had diagnosed the thymic carcinoma.
MATERIALS AND METHODS

Patients
Medical records and specimens from patients treated with thymic epithelial neoplasms at the Mayo Clinic were reviewed. Three pathologists (A.C.R., E.S.Y. and M.C.A.), blinded to the outcome, reviewed haematoxylin-eosin slides from all patients and classified all cases according to the current WHO [6] . Patients were divided into a study group and a disagreement group (Fig. 1) . The study group comprised only cases in which all three pathologists agreed independently upon a diagnosis of thymic carcinoma. The histological subtype of thymic carcinomas was established by consensus based on the WHO classification of thymic carcinomas. The study group was used for all assessments and statistical analysis to avoid problems of interobserver variability. Based on the degree of cytological atypia and tumour type, for some analyses, the study group was further divided into a group of low-intermediate-grade tumours and a group of high-grade tumours (Fig. 1 ).
The disagreement group included cases in which pathologists disagreed upon the histological diagnosis but at least one pathologist diagnosed the case as the thymic carcinoma. This group was used to study the significance of interobserver variability.
In all cases, clinical and radiological features were suggestive of the thymic origin, and no other primary tumours that could resemble the histological features seen in the thymic neoplasm were known.
Patients were staged according to the modified Masaoka staging [7] and the tumour-node metastasis (TNM) stage that was proposed by the current WHO [8] . The study was approved by the Mayo Clinic Institutional Review Board (#08-003478).
Histopathological criteria
Cases were classified according to the current WHO. Thymic carcinomas lacked the organotypic architecture of thymomas. Neoplastic cells were usually more atypical and grew in nests or sheets in a desmoplastic-type stroma.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks were cut at 4 μm. Slides were stained with haematoxylin-eosin. In selected cases, consecutive slides were stained with monoclonal antibodies against the desmoglein-3 antigen (DSG-3) (clone 5G11, Novus, CO) to evaluate for squamous differentiation. DSG-3 localizes to the cell membrane.
Statistical analysis
The patient characteristics in the study and disagreement groups were summarized with frequencies and percentages for categorical data and with medians and ranges for continuous data. The characteristics at the time of diagnosis/surgery were compared between groups with χ 2 tests (or Fisher's exact test where appropriate) for categorical data and with two-sample t-tests (or Wilcoxon rank-sum tests where appropriate) for continuous data. The outcomes considered (separately) were death and recurrence or new metastasis during the follow-up. The Kaplan-Meier method was used to estimate the median survival and 5-year survival and associations between the outcomes vs clinical characteristics were assessed with the Cox proportional hazards regression models. All analyses were conducted with SAS version 9 (Cary, NC, USA). P-values of <0.05 were considered statistically significant.
RESULTS
Study group
In 30 cases, pathologists independently diagnosed the thymic carcinoma. Clinical data were available for 29 patients, and this group forms our study group. Most thymic carcinomas (13 of 30, 43.3%) were squamous cell carcinomas (moderately differentiated, n = 5; poorly differentiated, n = 8) followed by undifferentiated carcinoma (4 of 30, 13.3%), sarcomatoid carcinoma (3 of 30, 10%), adenocarcinoma (3 of 30; moderately differentiated, n = 2; poorly differentiated, n = 1), small-cell carcinoma (2 of 30, 6.7%) and large-cell neuroendocrine carcinoma, atypical carcinoid tumour, clear cell carcinoma, mucoepidermoid carcinoma and moderately differentiated adenosquamous cell carcinoma (1 of 30, 3.3%, each) subtypes.
Clinical data are summarized in Table 1 . Twenty-five (of 29, 86.2%) patients in the study group had symptoms at presentation including chest pain (n = 12), shortness of breath (n = 9), weight loss (n = 5), cough (n = 5), back discomfort/pain (n = 2) and/or superior vena cava (SVC) syndrome, neck swelling, pneumonia, chest discomfort, dysphagia, diffuse pain, varicosis on the chest, night sweats, loss of consciousness and/or fatigue (n = 1, each). Fourteen patients had multiple symptoms at presentation. One patient had increased ANA titres but no patient was diagnosed with myasthenia gravis, another paraneoplastic syndrome or autoimmune disorder. Seventeen (of 29, 58.6%) patients had a preoperative biopsy. The patient with an atypical carcinoid tumour had multiple endocrine neoplasia (MEN) I syndrome. . Among the patients with positive LNs, the median number of positive LNs was 1 (range: 1-4). In the majority of the cases, mediastinal LNs were derived from the main specimen (n = 14). In four (of 14) patients in whom LNs were sampled off the specimen, there were also separately submitted hilar (n = 1), paratracheal (n = 2), lower paratracheal or subcarinal (n = 1) LNs. In one case, perithyroid LNs were sampled off the specimen and delphian, and neck level IV LNs were separately submitted. In other cases, anterior mediastinal (n = 1) or hilar (n = 1) LNs were separately submitted. In one case, the location of the LN was unknown. The majority of patients (17 of 29, 58.6%) underwent complete resection of the tumour. Eleven (of 29, 37.9%) had an incomplete resection of the thymic carcinoma, while one patient underwent an open biopsy. The size of the tumour in the resection specimen was available in 21 (of 28) cases with a median size of 6.0 cm (range: 2.1-14.5 cm). Twenty-two (of 27, 81.5%) patients underwent additional therapy as outlined in Table 1 .
Four (of 29, 13.8%) patients had metastasis at diagnosis; 12 (of 29) developed metastasis/recurrence post-treatment. Metastases were identified in the liver (n = 3), bone (n = 3), LN (n = 3; neck, posterior mediastinum), lung (n = 2), pleura (n = 2), upper gastrointestinal tract (n = 1), ovary (n = 1), and adrenal gland (n = 1). The follow-up was available in 29 patients. The median followup time was 1.6 years (range: 18 days-8.9 years) with a median time to death of 2.8 years [Kaplan-Meier estimate; 95% confidence interval (CI): 1.0-6.6 years]. The estimated 5-year survival was 35.6% (95% CI: 13.9-57.3%) and the recurrence/metastasisfree survival was 34.2% (95% CI: 8.8-59.6%).
Univariate analysis (Table 2) showed that the overall survival was significantly associated with weight loss at presentation [hazard ratio (HR) for weight loss yes vs no: 3.33, P = 0.02] but not with Masaoka stage, TNM stage, or WHO type of thymic carcinomas. There was no statistical significant difference in overall or disease-free survival between patients with low-intermediateand high-grade thymic carcinomas. However, univariate analysis revealed that the adenocarcinoma subtype was associated with the disease-free survival.
Disagreement group
In 29 cases, pathologists did not agree upon a single diagnosis but one or two pathologists diagnosed a case as the thymic carcinoma. The most common disagreement was between WHO type B3 thymoma and thymic carcinoma ( Fig. 2 ; 21/29, 72.4%) followed by type A thymoma vs thymic carcinoma (2/29, 6.9%), type B2 vs B3 thymoma vs thymic carcinoma (2/29), type B2 thymoma vs thymic carcinoma (2/29), atypical carcinoid tumour vs micronodular thymoma with lymphoid stroma (1/29, 3.4%) and atypical carcinoid tumour vs type B3 thymoma vs thymic carcinoma (1/29) .
Clinical data were available in all patients and are summarized in Table 1 . Twenty-five (of 29, 86.2%) patients had symptoms at presentation including weight loss (n = 5), shortness of breath (n = 4), cough (n = 3), chest pain (n = 2), SVC syndrome (n = 2), dysphagia (n = 2) and fever, chest discomfort, atrial fibrillation or hoarseness (n = 1, each). Six patients had multiple symptoms at presentation. Eleven (of 29, 37.9%) patients had myasthenia gravis. One of the patients with myasthenia gravis also had inflammatory myopathy and autoimmune enteropathy and colopathy. Another patient had idiopathic thrombocytopenic purpura but not myasthenia gravis. Ten (of 29, 34.5%) patients underwent a preoperative biopsy. Table 1 summarizes surgical treatments, Masaoka staging, TNM staging and follow-up. Regional LNs available in 10 patients (of 29, 34.5%) were positive in 3 (of 10, 30%). The median number of sampled LNs was 5 per case (range: 1-13). Among the patients with positive LNs, the median number of positive LNs was 1 (range: 1-2). In the majority of cases, mediastinal LNs were derived from the main specimen (n = 4). In other cases, paratracheal, left hilar, preaortic or left subclavian (n = 1, each) LNs were separately submitted. In one case, the location of the LN was unknown. The majority of patients (21 of Table 1 .
Two (of 29, 6.9%) patients had metastasis at diagnosis, and eight (of 29) developed metastasis/recurrence post-treatment. Metastases were identified in the lung (n = 5), liver (n = 2), bone (n = 1), brain (n = 1), chest wall (n = 1), LN (n = 1; right retrocrural), spine (n = 1) and pancreas (n = 1). The Follow-up was available in (Table 3) showed that tumour size was significantly associated with disease-free survival (HR = 1.22 for 1-cm increase in tumour size, P = 0.031). Masaoka stage, TNM stage and WHO type of thymic carcinomas were not associated with the overall or disease-free survival.
Comparison between study and disagreement group
Both the study group and the disagreement group were similar in regard to the patient age and a slight male predominance (Table 1 ). In the study group, a significantly larger number of patients presented with chest pain (P = 0.005). Significantly more patients had an autoimmune disease in the disagreement group, whereas no patient in the study group had an autoimmune disease (P = 0.0003). Furthermore, there was a statistically significant difference between both groups in regard to the TNM stage with patients having higher TNM stages in the disagreement group (P = 0.025). More patients underwent complete resection in the disagreement group than in the study group (72.4 vs 58.6%, respectively), although the difference was not statistically significant. Significantly more patients received additional therapy in the study group in comparison with the disagreement group (P = 0.044). The risk of death was significantly higher in the study group than the disagreement group (HR = 2.44, P = 0.025; Fig. 3A) . The median time to death was shorter in the study group in comparison with the disagreement group (2.8 vs 8.9 years, respectively). Similarly, the estimated 5-year survival was lower in the study group than in the disagreement group (35.6 vs 64.9%, respectively). Further, although the number of patients with metastasis at diagnosis was not significantly different, the risk of recurrence/metastasis post-treatment was significantly higher in the study group when compared with the disagreement group (HR = 3.22, P = 0.01; Fig 3B) . In addition, the recurrence/metastasis-free survival was lower in the study group than in the disagreement group (34.2 vs 78.1%).
DISCUSSION
Our study indicates that thymic carcinomas exhibit an aggressive behaviour. Most of our study patients (86%) had symptoms at the time of diagnosis, most commonly chest pain and shortness of breath. Our results support previous studies in which 52-76% of patients with a thymic carcinoma presented with symptoms [9, 10] . Although chest pain was most common in one study [9] , SVC syndrome was the leading symptom in the other [10] . These symptoms are in general a reflection of the space-occupying character of thymic carcinomas, indicating that these tumours are often diagnosed at an advanced stage. Indeed, most patients with a thymic carcinoma are diagnosed at high Masaoka and TNM stages. In our study group, the majority of patients presented with tumours at Masaoka stage III and TNM stage III or 
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higher (79% and 79% of study patients, respectively), and none of our study group patients had Masaoka or TNM stage I tumours. The median tumour size in our study population was 6.0 cm with tumours as large as 14.5 cm. These observations are similar to other studies including a series by Okereke et al. [3] . In that series, 56% of the patients with thymic carcinomas presented with Masaoka stage III or IV disease compared with only 39% of patients with thymomas. Other studies of thymic carcinomas also showed that the majority of patients presented with Masaoka stage III disease [10, 11] and only occasional patients had Masaoka stage I tumours [9] . Reported mean tumour sizes in the literature were similar to those in our study, ranging between 6.0 and 7.0 cm (range: 2.0-15.0 cm) [9, 10] . High rates of metastasis and recurrence in patients with thymic carcinomas also reflect an aggressive behaviour. In our study group, four (13.8%) patients already had metastasis at the time of diagnosis, and 12 of 29 patients developed a new metastasis/recurrence post-treatment. Similarly, Hosaka et al. [10] found recurrences in 50% of patients who underwent complete resection of thymic carcinomas. Moreover, prognosis appears poor in these patients. Although a single patient in our study group had a relatively long survival of 8.9 years, the median time to death was only 2.8 years with an estimated 5-year survival of 35.6% and the recurrence/metastasis-free survival of 34.2%. These findings are comparable with other studies that showed an overall median survival time of 2.0-3.65 years [9, 11] , an overall cumulative survival of 46.7% at 3 years [11] and 5-year survival rates of 27.5-50.5% [9, 12] . In only 59% of our study patients, complete tumour resection could be achieved; in all other cases, the extension of the tumour did not allow for complete resection. In the literature, complete tumour resectability ranged from 21 to 87.5%, although designs varied among studies with some including all patients with thymic carcinomas whereas others, such as ours, only included patients who underwent surgery with the intent of curative resection [9-11, 13, 14] . Although evidence suggests that complete resection of thymic epithelial tumours is a prognostical factor [13] that appears controversial for thymic carcinomas. In fact, we were not able to show a significant association between complete tumour resection and overall survival or disease-free survival. Similarly, Okereke et al. [3] , who reported R0 (complete) resection in 14 (of 16) thymic carcinoma patients, did not show any association of complete tumour resection with outcome. In contrast, in other studies, tumour resectability was a prognostical factor in thymic carcinomas [9, 10, 14, 15] . Differences in the outcome depending on tumour resectability among these studies might stem from variations in additional treatment strategies, different tumour stages of the respective patient population, small study groups that hamper statistical analysis or differences in the histopathological diagnosis. To our knowledge, our study is the only one that solely used cases that were independently diagnosed by multiple thoracic pathologists as thymic carcinoma. In the study by Hosaka et al. [10] , two pathologists independently evaluated all cases; however, the final diagnosis was reached by consensus in some cases. Thymic carcinomas are heterogeneous tumours. The current WHO [6] recognizes thymic carcinomas as a separate entity and distinguishes multiple subtypes. In our study, squamous cell carcinoma was the most common subtype followed by undifferentiated and sarcomatoid subtypes. Other subtypes were rather infrequent. Like ours, the majority of studies on thymic carcinomas encompass predominantly squamous cell carcinomas [9] [10] [11] 16] . In the study by Okereke et al. [3] , undifferentiated and squamous cell carcinomas were equally common, followed by a 'mixed' cell type. The prognostical significance of a thymic carcinoma subtype is still controversial. In our study, some evidence was found to indicate that an adenocarcinoma subtype was associated with a higher risk of recurrence/metastasis. However, our analysis was based on a small sample size (only three patients in this subtype) and therefore the statistical results are not stable and have to be interpreted with caution. Liu et al. [9] divided patients into low-vs high-grade tumours. Low-grade tumours included 'epidermoid' carcinomas (conceivably squamous cell carcinomas), carcinoids and mucoepidermoid carcinoma, whereas high-grade tumours included poorly differentiated carcinoma, clear cell carcinoma, small-cell carcinoma, adenocarcinoma and neuroendocrine carcinoma. The authors showed that patients with low-grade tumours had a significantly better survival than patients with high-grade tumours. Hosaka et al. [10] confirmed that histology is associated with overall survival. Patients with low-or intermediate-grade histology had a significantly better prognosis than those with high-grade histology. We were not able to confirm these results in our study. When study group patients were divided into groups with low-intermediategrade vs high-grade thymic carcinomas, no statistical significantly difference was identified in the overall or disease-free survival between these two groups.
In our study, weight loss was the only clinical feature significantly associated with survival. There was no association with Masaoka staging. In contrast, Liu et al. [9] showed a significantly better survival of patients with Masaoka stage III vs stage IV disease. In the review of 19 studies on thymic carcinomas by Chung [16] , stage I and II tumours demonstrated the best survival. Hosaka et al. [10] also showed that the Masaoka stage is an independent factor for the overall survival with patients with Masaoka II and III thymic carcinomas having a significantly better prognosis than patients with Masaoka IV thymic carcinomas. The differences in prognosis between those studies might be a consequence of several variables. (i) No uniform or standard management protocols have been established for thymic carcinomas. In part, this is probably due to the rarity of the disease and therefore lack of large and prospective studies. Studies such as ours usually include patients accrued over a large period of time in order to achieve a sufficient patient number. Subsequently, additional treatment methods varied between individual patients and between studies, because the decision to use neoadjuvant and/or adjuvant treatment was largely made individually. (ii) Interobserver variability in diagnosis might contribute to the variability in prognosis. (iii) The small number of cases in all the studies on thymic carcinomas make statistical analysis challenging and results are often rather unstable.
Similarly to additional therapies, systematic LN dissection was not the standard of care and in fact was not routine in our study nor did it appear to be a routine procedure in other studies. In our study, regional LNs were available in 65.5% of the study patients and were positive in 36.8% of those.
Although the majority of patients with positive LNs had stage N1 disease, a single patient had stage N2 disease in our study. None of the patients were diagnosed with N3 disease at resection. Similar results were shown by Hosaka et al. [10] with mediastinal LN dissection in 61.9% of the patients and with positive LNs in 46.1%. The lack of standardized lymph node dissection poses challenges for the TNM system classification, and although it has been established for most tumours, its use remains controversial for thymic carcinomas. Although some authors consider the TNM classification more useful for thymic carcinomas than for thymomas, none of the studies on thymic carcinomas used this classification [17] . In our study, the TNM stage was not associated with prognosis.
In addition to the study group, we also included a disagreement group to evaluate the impact of interobserver agreement for the histological diagnosis of thymic carcinomas on clinical features and outcome. In our study, the most common disagreements occurred between B3 thymomas and thymic carcinomas (21 of 29 cases). Other disagreements such as type A thymoma vs thymic carcinoma or type B2 thymoma vs thymic carcinoma were infrequent. Our results support previous interobserver agreement studies, although only a few have addressed this issue in thymic epithelial neoplasms [4, 5, 18] . For instance, Verghese et al. [5] reported a κ value of only 0.48 (moderate agreement) for type B3 vs thymic carcinomas when a panel of 17 pathologists reviewed thymic epithelial neoplasms according to the current WHO classification. Furthermore, a meta-analysis of 15 publications by Marchevsky et al. [19] revealed a high variability of the proportions of different subtypes of thymomas. Although the criteria for the classification of thymic epithelial neoplasms are defined by the current WHO, Marchevsky et al. concluded that individual pathologists might use those criteria differently. Our results highlight that interobserver agreement has an effect on clinical features and outcomes of thymic carcinoma patients. Indeed, the comparison between the study group and the disagreement group indicated that tumours in the study group in which all pathologists agreed upon a diagnosis of thymic carcinomas might be more aggressive than those in the disagreement group in which the diagnosis of thymic carcinomas was not supported by all pathologists. Indeed, more patients presented with metastasis at the time of diagnosis in the study group, and the number of patients with subsequent recurrence/metastasis was significantly higher in the study group. Despite the fact that TNM staging was higher for the disagreement group, the risk of death and the risk of developing recurrence/metastasis was significantly higher in the study group. The median time to death was also shorter in the study group, and the estimated 5-year survival and the recurrence/metastasis-free survival were lower. Clinically, patients were different in that more patients in the study group presented with chest pain and had no autoimmune or paraneoplastic syndromes compared with the disagreement group. These findings suggest that some of the patients in the disagreement group are not true thymic carcinomas but rather thymomas. These findings further imply that interobserver agreement plays a significant role when evaluating the outcomes of patients with thymic carcinomas and might explain, at least in part, the differences in the outcomes of thymic carcinoma studies.
Thymomas are commonly associated with myasthenia gravis, and myasthenia gravis occurs in 15-80% of patients with a thymoma, especially in type B2 and B3 thymomas [20, 21] . Other paraneoplastic conditions such as pure red cell aplasia and hypogammaglobulinemia occur in 2-5% of thymoma patients [13] . In contrast, the thymic carcinoma does not appear to be associated with autoimmune or other paraneoplastic syndromes. Indeed, none of our study patients with a thymic carcinoma were diagnosed with an autoimmune disease. Although the literature on clinical findings in thymic carcinoma patients is sparse, some authors also reported on the absence of myasthenia gravis or other paraneoplastic syndromes in patients with a thymic carcinoma [3, 11] , whereas others described their decreased incidence in thymic carcinoma patients when compared with patients with a thymoma [16] . For instance, Liu et al. [9] reported myasthenia gravis in 7.9% of 38 patients with a thymic carcinoma. In addition, a case of a 23-year old man with lymphoepithelioma-like thymic carcinoma and paraneoplastic polymyositis-was reported [22] . Hosaka et al. [10] described one patient with dermatomyositis in a case series of 21 patients with a thymic carcinoma. The low association or the absence of the association of thymic carcinomas with myasthenia gravis or paraneoplastic syndromes might indicate a pathogenesis of thymic carcinomas that is distinct from thymomas. It might be speculated that the lack of autoimmune T cell production in thymic carcinomas is due to the absence of thymocytes [6] or due to the unique features of the neoplastic cells. However, a mechanism has not been identified. Nevertheless, the fact that 12 (of 29) patients in the disagreement group had an autoimmune disease supports that not all of the cases in this group are true thymic carcinomas and are likely thymomas. Therefore, if a thymic carcinoma is difficult to discern from a thymoma based on morphological features, clinical information might also be a helpful adjunct in the diagnosis.
The authors recognize several potential shortcomings of the study. Although our study is one of the largest studies concerning patients with a thymic carcinoma who underwent surgical therapy, it is still relatively small in regard to meaningful statistical analysis. Although statistical analysis was attempted, given the large number of variables relative to the less number of 'events', the results are not very stable. Only larger, multicentre studies or meta-analyses, in our opinion, might be able to overcome this hurdle. However, even multicentre studies are probably difficult to interpret given the present lack of the standard treatment of thymic carcinomas. Because of the rarity of the disease resulting in limited studies, therapy regimens are largely on an individual basis. Furthermore, again because of the rarity of the disease, many studies including ours encompass patients accrued over a long-time period with different treatment strategies and chemotherapy agents and radiation opportunities.
However, despite these potential shortcomings, our study, for the first time, emphasizes the significance of the pathological diagnosis for outcome studies in thymic carcinomas. Our study further helps to recognize the clinicopathological features of thymic carcinomas and might facilitate the development of treatment standards and options.
